source
- House lawmakers hear mixed views on credentialing for psychedelic providersAs psychedelic medicines move closer to market, two members of the U.S. House are outlining how the drugs might be rolled out and what accompanying legislation could look like. The focus of their…
- Lilly's amylin-Zepbound combo shows 23% weight loss in type 2 diabetes patientsEli Lilly reported that its amylin‑Zepbound combination, eloraTZP, produced an average 23.3% weight loss in adults with type 2 diabetes who were also obese or overweight. The result was derived fro…